Correction to: Journal of Molecular Medicine (2018) 96:1307–1318
In Fig. 1b, upper part, the cell viability counts after treatment with cisplatin and TSA in T24 cells was by mistake a duplication of the image for NTUB1 on the left. In the corrected version of Fig. 1, the image was replaced appropriately. The authors claim that this correction does not affect the message and conclusion of this study, and apologize for the oversight.
TSA inhibits cell viability and enhances cytotoxicity of chemotherapeutic agents (cisplatin, gemcitabine, or doxorubicin) in human UC cells. a, b NTUB1 (a) and T24 (b) cells were treated with various concentrations of TSA (0.1 – 1 μM) for 48 h in combination with various concentrations of chemotherapeutic agents (cisplatin 2.5 – 30 μM, gemcitabine 0.5 – 20μM, and doxorubicin 0.05 – 5 μM). Cell viability was assessed by MTT assay
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1007/s00109-018-1697-7
Rights and permissions
About this article
Cite this article
Lin, WC., Hsu, FS., Kuo, KL. et al. Correction to: Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma. J Mol Med 97, 435–436 (2019). https://doi.org/10.1007/s00109-019-01748-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-019-01748-2